
How the First-Line EGFR-Mutated NSCLC Landscape Has Changed
Lyudmila Bazhenova, MD, of University of California San Diego Moores Cancer Center, opens this OncLive News Network discussion with Edward S. Kim, MD, MBA, of City of Hope Orange County, by asking how first-line treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has changed. Dr Kim recalls when all EGFR mutations were grouped into one bucket and treatment meant a single tyrosine kinase inhibitor (TKI), with rash and diarrhea as the main problems to manage.
Lyudmila Bazhenova, MD, of University of California San Diego Moores Cancer Center, opens this OncLive News Network discussion with Edward S. Kim, MD, MBA, of City of Hope Orange County, by asking how first-line treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has changed. Dr Kim recalls when all EGFR mutations were grouped into one bucket and treatment meant a single tyrosine kinase inhibitor (TKI), with rash and diarrhea as the main problems to manage. He says the field now separates sensitizing, less common, and resistance mutations, and that therapies have become more potent with different or fewer toxicities. With several first-line options and new data arriving all the time, he says it is hard to pick the best treatment for each person, and the choice is not yet defined by the exact type of sensitizing mutation. Dr Bazhenova previews the program’s focus on first-line choices, options at progression, and patient communication.
Related to this article








